Narayana Hrudayalaya Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹2,151Cr
- +61.1% YoY
- +30.8% QoQ
- Net profit
- ₹127Cr
- −34.2% YoY
- −50.8% QoQ
- Margin
- 17%
- −6 pp YoY
- −7 pp QoQ
Guidance rank: #27 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
The short version
India business: Expected to sustain double-digit like-to-like hospital revenue growth till new hospitals commission (Page 12). India business is expected to sustain double-digit revenue growth with continued margin expansion driven by transformation programs and payor mix optimization initiatives.
From Narayana Hrudayalaya Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- India business: Expected to sustain double-digit like-to-like hospital revenue growth till new hospitals commission (Page 12).
- Oncology and cardiac: Projected to account for more than half of revenue going forward, with oncology potentially increasing by 20% (Page 9).
- Expansion focus: Consolidating core markets like Bangalore and Kolkata, with investments in new flagship facilities (Page 14).
- UK operations: Growth expected through improving performance and expanding private market share, though margins will differ from other markets (Page 15).
- Cayman operations: Expected to sustain revenue levels (Page 14).
2 more points from Narayana Hrudayalaya Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Narayana Hrudayalaya Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- India CapEx: Planned INR 1000 crore (internal accruals and debt funding); actual closer to INR 3000 crore for expansion, mainly in Bangalore, Kolkata, and Raipur clusters (Page 12, 14, 25).
- Addition of four DaVinci robotic surgery systems across hospitals in India next year for advanced surgical capabilities (Page 23).
- Minor equipment and sterilization units CapEx in Birmingham (UK) has mostly been completed; no major remaining CapEx (Page 17).
- Investment in oncology joint ventures in India: Everhope Oncology (chemo centers in Delhi/Gurgaon) and SSO Oncology in Mumbai with plans to expand; no earmarked further investments yet pending business trajectory (Page 25).
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Narayana Hrudayalaya Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Narayana Hrudayalaya Ltd said on order book & pipeline — free account, 30 seconds.
Narayana Hrudayalaya Ltd — Quarterly revenue & net profit
Narayana Hrudayalaya Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 2,151 | 1,335 | +61.1% | 1,644 | +30.8% |
| Operating profit (EBITDA) | 365 | 307 | +18.9% | 401 | -9% |
| Operating margin | 17% | 23% | -6 pp | 24% | -7 pp |
| Profit before tax | 149 | 219 | -32% | 296 | -49.7% |
| Net profit (PAT) | 127 | 193 | -34.2% | 258 | -50.8% |
| EPS (₹) | 6.20 | 9.44 | -34.3% | 12.64 | -50.9% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.8K Cr, net profit ₹301 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Narayana Hrudaya's management said in earlier quarters
Others in Healthcare Services this season
- Vijaya Diagnostic Centre (Q3 FY26)
FY '27 capex of INR 100-120 crores planned, supporting network expansion (Page 5). Key concall takeaways from Vijaya Diagnostic Centre's Q3 FY26 earnings call —
- Aster DM Quality (Q3 FY26)
Mature hospitals show steady revenue growth of 14%, hospitals 3-7 years old growing at 10%, and new assets under 3 years growing at 19%. Key concall takeaways…
- Chandan Healthca (Q3 FY26)
The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion. Key concall takeaways from Chandan…
- Rainbow Childrens Medicare (Q3 FY26)
Revenue growth for the quarter was 12% YoY; 9% for the first 9 months of the financial year. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Narayana Hrudayalaya Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Narayana Hrudayalaya Ltd Q3 FY26 results?
India business: Expected to sustain double-digit like-to-like hospital revenue growth till new hospitals commission (Page 12). India business is expected to sustain double-digit revenue growth with continued margin expansion driven by transformation programs and payor mix optimization initiatives.
What is Narayana Hrudayalaya Ltd share price analysis?
Narayana Hrudayalaya Ltd currently shows a neutral. The stock trades at a P/E of 45.1 with a market cap of ₹38,892 Cr. Investors should review the full earnings analysis for detailed insights.
Is Narayana Hrudayalaya Ltd planning capital expenditure?
India CapEx: Planned INR 1000 crore (internal accruals and debt funding); actual closer to INR 3000 crore for expansion, mainly in Bangalore, Kolkata, and Raipur clusters (Page 12, 14, 25).
Keep Narayana Hrudayalaya Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
